Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer

References

• Luo W , WangZ , ZhangTet al. Immunotherapy in non-small-cell lung cancer: rationale, recent advances and future perspectives. Precis Clin. Med.4(4), 258–270 (2021).
   PubMedGoogle Scholar
• OPDIVO (nivolumab) Prescribing Information . Bristol-Myers Squibb Company, NJ, USA (2023). (Accessed 5April2023). https://packageinserts.bms.com/pi/pi_opdivo.pdf
   Google Scholar
• KEYTRUDA (pembrolizumab) Prescribing Information . Merck Sharp & Dohme LLC, NJ, USA (2023). (Accessed 5April2023). www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• LIBTAYO (cemiplimab) Prescribing Information . Regeneron Pharmaceuticals, NY, USA (2023). (Accessed 30May2023). www.regeneron.com/downloads/libtayo_fpi.pdf
   Google Scholar
• TECENTRIQ (atezolizumab) Prescribing Information . Genentech, CA, USA (2023). (Accessed 30May2023). www.gene.com/download/pdf/tecentriq_prescribing.pdf
   Google Scholar
• IMFINZI (durvalumab) Prescribing Information . AstraZeneca, DE, USA (2022). (Accessed 30May2023). https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9496217c-08b3-432b-ab4f-538d795820bd/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf
   Google Scholar
• YERVOY (ipilimumab) Prescribing Information . Bristol-Myers Squibb Company, NJ, USA (2023). (Accessed 5April2023). https://packageinserts.bms.com/pi/pi_yervoy.pdf
   Google Scholar
• IMJUDO (tremelimumab) Prescribing Information . AstraZeneca, DE, USA (2022). (Accessed 30May2023). https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0102c6fd-de8a-4b43-afa3-2a2c2115d472/0102c6fd-de8a-4b43-afa3-2a2c2115d472_viewable_rendition__v.pdf
   Google Scholar
• AVASTIN (bevacizumab) Prescribing Information . Genentech, CA,USA (2023). (Accessed 5April2023). www.gene.com/download/pdf/avastin_prescribing.pdf
   Google Scholar
• Lu Y , ZhangX , NingJ , ZhangM. Immune checkpoint inhibitors as first-line therapy for non-small-cell lung cancer: a systematic evaluation and meta-analysis. Hum. Vaccin Immunother.19(1), 2169531 (2023).
   PubMed Web of Science ®Google Scholar
• Siciliano MA , CaridàG , CilibertoDet al. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open7(3), 100465 (2022).
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration . FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) (2023). (Accessed 6April2023). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1
   Google Scholar
• United States Food and Drug Administration . FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC (2023). (Accessed 6April2023). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc
   Google Scholar
• Vellanki PJ , MulkeyF , JaigirdarAAet al. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic non-small-cell Lung Cancer, A Collaborative Project Orbis Review. Clin. Cancer Res.27(13), 3522–3527 (2021).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , LeeJS , CiuleanuTEet al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J. Clin. Oncol.41(6), 1200–1212 (2023).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , Paz-AresL , BernabeCaro Ret al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med.381(21), 2020–2031 (2019).
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG , RamalingamSS , CiuleanuTEet al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J. Thorac. Oncol.17(2), 289–308 (2022).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , CiuleanuTE , CoboMet al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol.22(2), 198–211 (2021).
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG , CiuleanuT-E , CoboMet al. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations. Journal of Thoracic Oncology18(2), 204–222 (2023).
   Web of Science ®Google Scholar
• Reck M , CiuleanuTE , CoboMet al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: checkMate 9LA 2-year update. ESMO Open6(5), 100273 (2021).
   PubMed Web of Science ®Google Scholar
• Reck M , BorghaeiH , O’byrneKJ. Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncol.15(19), 2287–2302 (2019).
   PubMed Web of Science ®Google Scholar
• Wei SC , AnangNaS , SharmaRet al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl Acad. Sci. USA116(45), 22699–22709 (2019).
   PubMed Web of Science ®Google Scholar
• Park R , LopesL , CristanchoCR , RianoIM , SaeedA. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Frontiers in Oncology10, 258 (2020).
   PubMed Web of Science ®Google Scholar
• Melero I , BermanDM , AznarMA , KormanAJ , PérezGracia JL , HaanenJ. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer15(8), 457–472 (2015).
   PubMed Web of Science ®Google Scholar
• Liu SV , RaiP , WangD , HuX , SchwarzenbergerPO. First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices. JTO Clin. Res. Rep.4(2), 100444 (2023).
   PubMedGoogle Scholar
• Velcheti V , HuX , YangL , PietanzaMC , BurkeT. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic non-small-cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1. Front Oncol.12, 834761 (2022).
   PubMed Web of Science ®Google Scholar
• Waterhouse D , LamJ , BettsKAet al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small-cell lung cancer. Lung Cancer156, 41–49 (2021).
   PubMed Web of Science ®Google Scholar
• Nguyen-Duc T , MulliganN , MannuGS , Bettencourt-SilvaJH. Deep EHR Spotlight: a Framework and Mechanism to Highlight Events in Electronic Health Records for Explainable Predictions. AMIA Jt Summits Transl. Sci. Proc.2021, 475–484 (2021).
   PubMedGoogle Scholar
• National Institutes of Health – National Cancer Institute . Side Effects of Cancer Treatment. (Accessed7 April 2023). www.cancer.gov/about-cancer/treatment/side-effects
   Google Scholar
• American Cancer Society . Chemotherapy for non-small-cell Lung Cancer (2020). (Accessed 7April2023). www.cancer.org/cancer/lung-cancer/treating-non-small-cell/chemotherapy.html
   Google Scholar
• Nurgali K , JagoeRT , AbaloR. Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?Front Pharmacol.9, 245 (2018).
   PubMed Web of Science ®Google Scholar
• Banz K , BischoffH , BrunnerMet al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer74(3), 529–534 (2011).
   PubMed Web of Science ®Google Scholar
• Gandhi L , Rodríguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , LuftA , VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• West H , MccleodM , HusseinMet al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology20(7), 924–937 (2019).
   PubMed Web of Science ®Google Scholar
• Socinski MA , JotteRM , CappuzzoFet al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med.378(24), 2288–2301 (2018).
   PubMed Web of Science ®Google Scholar
• Jiang P , MaoZ , WangQet al. An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic non-small-cell Lung Cancer. Front Oncol.11, 698199 (2021).
   PubMed Web of Science ®Google Scholar
• O’byrne K , PopoffE , BadinFet al. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis. Lung Cancer177, 11–20 (2023).
   PubMed Web of Science ®Google Scholar
• Pang LL , GanJD , HuangYHet al. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer23(1), 72 (2023).
   PubMed Web of Science ®Google Scholar